Patient characteristics and disposition
Description . | N = 54 . |
---|---|
Sex, n (%) | |
Male | 45 (83.3) |
Female | 9 (16.7) |
Age, y, median (range) | 62.5 (37-82) |
WHO performance status score, n (%) | |
0 | 17 (31.5) |
1 | 32 (59.3) |
2 | 5 (9.3) |
Stage of disease at baseline (Rai classification) | |
Low risk | 5 (9.3) |
Intermediate risk | 12 (22.2) |
High risk | 36 (66.7) |
Missing | 1 (1.9) |
Extent of CLL, n (%) | |
Bulky lymphadenopathy (≥1 node ≥5 cm in diameter) | 43 (79.6) |
Splenomegaly | 20 (37.0) |
Hepatomegaly | 3 (5.6) |
Thrombocytopenia (platelets <100 × 109/L) | 34 (63.0) |
Anemia (Hb <110 g/L) | 25 (46.2) |
Neutropenia (ANC <1.5 × 109/L) | 15 (27.7) |
ALC cells × 109/L, median (range) | 10.8 (0.1-185.2) |
CLL genetics, n (%) | |
Unmutated IgHV | 49 (90.7) |
del17p and/or TP53 mutation | 13 (20.4) |
Prior therapies, n, median (range) | 5 (2-14) |
Prior therapy type, n (%) | |
Purine analog | 54 (100.0) |
Rituximab | 52 (96.0) |
Alkylating agent | 47 (87.0) |
Alemtuzumab | 19 (35.2) |
Anthracycline/anthracenedione | 18 (33.3) |
Disease status (investigator judgment), n (%) | |
Relapsed | 16 (29.6) |
Refractory (to the most recent prior therapy) | 38 (70.4) |
Idelalisib starting dose level, n (%) | |
50 mg/dose bid | 5 (9.3) |
100 mg/dose bid | 11 (20.4) |
300 mg/dose qd | 10 (18.5) |
150 mg/dose bid | 11 (20.4) |
200 mg/dose bid | 10 (18.5) |
350 mg/dose bid | 7 (13.0) |
Duration of idelalisib therapy, mo, mean (range) | 15 (0.2-48.7) |
Treatment disposition, n (%) | |
Completed primary study (≥48 wk of idelalisib therapy) | 25 (46.3) |
Discontinued primary study therapy | 29 (53.7) |
Enrolled in extension study | 23 (38.9) |
Ongoing | 8 (14.8) |
Discontinued extension study therapy | 15 (27.8) |
Primary reasons for discontinuation from primary or extension study therapy* | |
Disease progression | 25† (46.3) |
AE | 7‡ (12.9) |
Death | 4 (7.4) |
Patient request | 3 (5.6) |
Other (lost to follow-up, other therapy, referred for transplantation) | 3 (5.6) |
Investigator request | 2§ (3.7) |
Description . | N = 54 . |
---|---|
Sex, n (%) | |
Male | 45 (83.3) |
Female | 9 (16.7) |
Age, y, median (range) | 62.5 (37-82) |
WHO performance status score, n (%) | |
0 | 17 (31.5) |
1 | 32 (59.3) |
2 | 5 (9.3) |
Stage of disease at baseline (Rai classification) | |
Low risk | 5 (9.3) |
Intermediate risk | 12 (22.2) |
High risk | 36 (66.7) |
Missing | 1 (1.9) |
Extent of CLL, n (%) | |
Bulky lymphadenopathy (≥1 node ≥5 cm in diameter) | 43 (79.6) |
Splenomegaly | 20 (37.0) |
Hepatomegaly | 3 (5.6) |
Thrombocytopenia (platelets <100 × 109/L) | 34 (63.0) |
Anemia (Hb <110 g/L) | 25 (46.2) |
Neutropenia (ANC <1.5 × 109/L) | 15 (27.7) |
ALC cells × 109/L, median (range) | 10.8 (0.1-185.2) |
CLL genetics, n (%) | |
Unmutated IgHV | 49 (90.7) |
del17p and/or TP53 mutation | 13 (20.4) |
Prior therapies, n, median (range) | 5 (2-14) |
Prior therapy type, n (%) | |
Purine analog | 54 (100.0) |
Rituximab | 52 (96.0) |
Alkylating agent | 47 (87.0) |
Alemtuzumab | 19 (35.2) |
Anthracycline/anthracenedione | 18 (33.3) |
Disease status (investigator judgment), n (%) | |
Relapsed | 16 (29.6) |
Refractory (to the most recent prior therapy) | 38 (70.4) |
Idelalisib starting dose level, n (%) | |
50 mg/dose bid | 5 (9.3) |
100 mg/dose bid | 11 (20.4) |
300 mg/dose qd | 10 (18.5) |
150 mg/dose bid | 11 (20.4) |
200 mg/dose bid | 10 (18.5) |
350 mg/dose bid | 7 (13.0) |
Duration of idelalisib therapy, mo, mean (range) | 15 (0.2-48.7) |
Treatment disposition, n (%) | |
Completed primary study (≥48 wk of idelalisib therapy) | 25 (46.3) |
Discontinued primary study therapy | 29 (53.7) |
Enrolled in extension study | 23 (38.9) |
Ongoing | 8 (14.8) |
Discontinued extension study therapy | 15 (27.8) |
Primary reasons for discontinuation from primary or extension study therapy* | |
Disease progression | 25† (46.3) |
AE | 7‡ (12.9) |
Death | 4 (7.4) |
Patient request | 3 (5.6) |
Other (lost to follow-up, other therapy, referred for transplantation) | 3 (5.6) |
Investigator request | 2§ (3.7) |